<DOC>
	<DOCNO>NCT01043991</DOCNO>
	<brief_summary>Primary endpoint : Is intracoronary injection single dose darbepoetin alpha , reperfusion patient hospitalize ST segment elevation myocardial infarction ( STEMI ) , able reduce infarct size ? In vivo study , many experiment evidence infarct size reduction , due anti-apoptotic compound , give reperfusion , cardiac ischemia . In human , post-conditioning offer protection , investigator previously show ( Staat P et al . Post-conditioning human heart . Circulation . 2005 112 ( 14 ) :2143-8 ) . Infarct size reduction could lead reduce rate complication ( heart failure , rhythmic complication ) finally , morbidity even mortality . This protection depend anti-apoptotic property ( Zhao ZQ et al . Inhibition myocardial injury ischemic postconditioning reperfusion : comparison ischemic preconditioning . Am J Physiology Heart Circ Physiology 2003 Aug ; 285 ( 2 ) : H579-88 ) . Many drug propose able mimic phenomenon . Among , many efficient toxic vivo difficult manage ( insulin , morphin ) . One promising agent could erythropoietin ( EPO ) ( Opie LH et al . Postconditioning protection infarcting heart . Lancet . 2006 ; 367 ( 9509 ) :456-8 ) . In order target ischemia-reperfusion injury , EPO impact well well demonstrate ( e.g . : Mudalagiri NR . Erythropoietin protect human myocardium hypoxia reoxygenation injury via phosphatidylinositol-3 kinase ERK1-2 activation . Br J Pharmacol . 2007 Oct 22 ) . The purpose study test hypothesis human , onset reperfusion , myocardial ischemia ( acute myocardial infarct ) . EPO could contribute protect myocardium ischemia-reperfusion injury . This impact could rely anti-apoptotic property .</brief_summary>
	<brief_title>Intracoronary Injection Epo After Myocardial Infarct `` Intra-CO-EpoMI ''</brief_title>
	<detailed_description>Multiple Centers . : 5 center locate France : - Montpellier - Clermont-Ferrand - Lyon - Marseille - Nîmes Study design : Open-label , placebo-controlled , single-blinded . Patient treatment group receive intracoronary single bolus EPO ( 150 µg ) , soon significant reperfusion obtain ( measure TIMI flow 2 3 ) . In control group , placebo use . Placebo must present exactly drug . Length Treatment : One shot reperfusion procedure . Follow-up Period : 72nd hour post-admission plasma kinetics cardiac enzymes 5th 7th day revascularization procedure MRI measurement , echocardiography3th month post-MI MRI , echocardiography3th month : phone contact . Sample Size : 27 patient arm , 54 patient total .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>ACS persistent ST elevation First episode Symptoms onset &lt; 12 hour Eligible angioplasty Culprit coronary artery occlude ( TIMI flow 01 ) admission , adequately reperfused ( TIMI flow 23 ) prior EPO injection Cardiogenic shock Cardiac arrest Currently receive EPO Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>STEMI</keyword>
	<keyword>AMI ,</keyword>
	<keyword>acute myocardial infarct</keyword>
	<keyword>Epo</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>ischemia-reperfusion</keyword>
	<keyword>apoptosis</keyword>
</DOC>